PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma
Status:
Terminated
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist
treatment leads to a high risk of bleeding.
Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to
reverse anticoagulation with concomitant administration of prothrombin complex concentrates
(PCCs) and vitamin K.
However, even if a reversion is performed, the prognostic of post-traumatic intracranial
bleeding remain bad.
The investigators hypothesize that, for patients admitted in an emergency department after a
minor head trauma and receiving anticoagulant treatment, a systematic preventive reversion
with PCCs can lead to a significant reduction of intracranial haemorrhage and can also
improve the neurological prognostic of patients versus the current strategy.
PREVACT will test this hypothesis, in an open label, randomized, multicentre, clinical trial
involving 400 patients.